TickerFacts.

Exelixis, Inc. (EXEL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2012-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$901.25M
Year ended 2026-01-02, Fiscal 2025
$999.81M
Trailing 12 months to 2026-07-03
+59.4%
3-year compound annual growth
+49.9%
5-year compound annual growth
2009-12-31: -$109.31M2010-12-31: -$80.85M2011-12-31: $96.36M2012-12-31: -$116.92M2013-12-31: -$197.59M2014-12-31: -$222.07M2016-01-01: -$120.02M2016-12-30: -$27.12M2017-12-29: $167.10M2018-12-28: $443.77M2020-01-03: $377.82M2021-01-01: $119.20M2021-12-31: $300.30M2022-12-30: $222.36M2023-12-29: $196.60M2025-01-03: $633.42M2026-01-02: $901.25M$901.25M
2009-12-31 EBITDA (USD) 2026-01-02
Period endedEBITDAChange YoYSource filing
2026-01-02, Fiscal 2025$901.25M+42.3%2026-02-10, From 2025-01-04
2025-01-03, Fiscal 2024$633.42M+222.2%2026-02-10, From 2023-12-30
2023-12-29$196.60M-11.6%2026-02-10, From 2022-12-31
2022-12-30$222.36M-26.0%2025-02-11, From 2022-01-01
2021-12-31$300.30M+151.9%2024-02-06, From 2021-01-02
2021-01-01, Fiscal 2020$119.20M-68.5%2023-02-07, From 2020-01-04
2020-01-03, Fiscal 2019$377.82M-14.9%2022-02-18, From 2018-12-29
2018-12-28$443.77M+165.6%2021-02-11, From 2018-01-01
2017-12-29$167.10Mn/m2020-02-25, From 2016-12-31
2016-12-30-$27.12Mn/m2019-02-22, From 2016-01-02
2016-01-01, Fiscal 2015-$120.02Mn/m2018-02-26, From 2015-01-03
2014-12-31-$222.07Mn/m2017-02-27, From 2014-01-01
2013-12-31-$197.59Mn/m2016-02-29, From 2013-01-01
2012-12-31-$116.92Mn/c2015-03-02, From 2012-01-01
2011-12-31$96.36Mn/m2014-02-20, From 2011-01-01
2010-12-31-$80.85Mn/m2013-02-21, From 2010-01-01
2009-12-31-$109.31Mn/a2012-02-22, From 2009-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Exelixis, Inc. (EXEL)2026-01-02$901.25M+42.3%
Qiagen N.V. (QGEN)2025-12-31$659.60M+119.2%
Moderna, Inc. (MRNA)2025-12-31-$2.86Bn/m
Halozyme Therapeutics, Inc. (HALO)2025-12-31$480.39M-14.5%
Bio-Techne Corp (TECH)2026-06-30$349.25M+64.6%
Novavax Inc (NVAX)2025-12-31$480.41Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$342.38Mn/m
Repligen Corp (RGEN)2025-12-31$133.91M+287.5%
ADMA Biologics, Inc. (ADMA)2025-12-31$199.54M+35.7%

Compare EXEL, QGEN, MRNA, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗